The memory binding test in a longitudinal study of cognitive aging and preclinical disease.

IF 2.6 3区心理学 Q3 NEUROSCIENCES

Neuropsychology Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI:10.1037/neu0000952

Stephanie Aghamoosa, Katrina S Rbeiz, Olivia Horn, Kathryn E Thorn, Andreana Benitez

{"title":"The memory binding test in a longitudinal study of cognitive aging and preclinical disease.","authors":"Stephanie Aghamoosa, Katrina S Rbeiz, Olivia Horn, Kathryn E Thorn, Andreana Benitez","doi":"10.1037/neu0000952","DOIUrl":null,"url":null,"abstract":"Objective: The Memory Binding Test (MBT) shows promise in detecting early cognitive changes associated with Alzheimer's disease (AD). This study assesses the psychometric properties (i.e., construct and criterion validity, test-retest reliability) of the MBT and its sensitivity to incipient disease and incident cognitive impairment.Method: One hundred forty-nine cognitively unimpaired adults ages 45-85 completed the MBT and neuropsychological tests at baseline; 132 returned for 2-year follow-up. Based on neuroradiological ratings of amyloid positron emission tomography and MRI markers at baseline, they were categorized as healthy (n = 94) or having preclinical disease (n = 55, either on the AD continuum or having non-AD pathologic change). Construct validity was assessed by the associations between MBT scores, demographics, and neuropsychological scores within the healthy group. Criterion validity was assessed by testing how MBT scores correlate with AD biomarkers, differ and discriminate between groups at baseline, and predict incident cognitive impairment.Results: MBT scores decreased with age and were strongly associated with memory and global cognition. MBT scores were largely not associated with amyloid, hippocampal volume, or AD signature cortical volume but related to white matter lesion volume in those with preclinical disease. The preclinical groups performed worse on MBT immediate free recall at baseline than the healthy group, but no scores predicted incident cognitive impairment at follow-up. Most scores demonstrated modest test-retest reliability.Conclusions: This study demonstrates that the MBT has adequate construct validity in cognitively unimpaired adults, moderate sensitivity to preclinical disease cross-sectionally, and limited prognostic utility. Careful consideration of demographic influences on score interpretation remains necessary. (PsycInfo Database Record (c) 2024 APA, all rights reserved).","PeriodicalId":19205,"journal":{"name":"Neuropsychology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1037/neu0000952","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The Memory Binding Test (MBT) shows promise in detecting early cognitive changes associated with Alzheimer's disease (AD). This study assesses the psychometric properties (i.e., construct and criterion validity, test-retest reliability) of the MBT and its sensitivity to incipient disease and incident cognitive impairment.

Method: One hundred forty-nine cognitively unimpaired adults ages 45-85 completed the MBT and neuropsychological tests at baseline; 132 returned for 2-year follow-up. Based on neuroradiological ratings of amyloid positron emission tomography and MRI markers at baseline, they were categorized as healthy (n = 94) or having preclinical disease (n = 55, either on the AD continuum or having non-AD pathologic change). Construct validity was assessed by the associations between MBT scores, demographics, and neuropsychological scores within the healthy group. Criterion validity was assessed by testing how MBT scores correlate with AD biomarkers, differ and discriminate between groups at baseline, and predict incident cognitive impairment.

Results: MBT scores decreased with age and were strongly associated with memory and global cognition. MBT scores were largely not associated with amyloid, hippocampal volume, or AD signature cortical volume but related to white matter lesion volume in those with preclinical disease. The preclinical groups performed worse on MBT immediate free recall at baseline than the healthy group, but no scores predicted incident cognitive impairment at follow-up. Most scores demonstrated modest test-retest reliability.

Conclusions: This study demonstrates that the MBT has adequate construct validity in cognitively unimpaired adults, moderate sensitivity to preclinical disease cross-sectionally, and limited prognostic utility. Careful consideration of demographic influences on score interpretation remains necessary. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

查看原文本刊更多论文

认知老化和临床前疾病纵向研究中的记忆结合测试。

目的记忆束缚测试（MBT）有望检测出与阿尔茨海默病（AD）相关的早期认知变化。本研究评估了记忆绑定测试的心理计量特性（即构建和标准效度、重测可靠性）及其对初发疾病和偶发认知障碍的敏感性：149名年龄在45-85岁之间、认知能力未受损的成年人完成了基线MBT和神经心理学测试；132人返回进行为期2年的随访。根据基线时淀粉样蛋白正电子发射断层扫描和磁共振成像标记物的神经放射学评级，他们被分为健康人（94 人）或临床前疾病患者（55 人，处于注意力缺失症连续体或无注意力缺失症病理改变）。结构效度通过健康组中 MBT 分数、人口统计学和神经心理学分数之间的关联进行评估。标准有效性是通过测试 MBT 分数与注意力缺失症生物标志物的相关性、基线时各组之间的差异和区别以及预测认知障碍事件来评估的：结果：MBT 分数随着年龄的增长而降低，并与记忆和整体认知密切相关。MBT评分与淀粉样蛋白、海马体积或AD标志性皮质体积基本无关，但与临床前疾病患者的白质病变体积有关。与健康组相比，临床前疾病组在基线MBT即时自由回忆中的表现更差，但没有得分能预测随访时出现的认知障碍。大多数分数显示出适度的测试-再测试可靠性：这项研究表明，MBT 在认知功能未受损的成年人中具有充分的构建有效性，对临床前疾病的横断面敏感性适中，但预后效用有限。仍有必要仔细考虑人口统计学对分数解释的影响。(PsycInfo Database Record (c) 2024 APA, 版权所有）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropsychology 医学-神经科学

CiteScore

4.10

自引率

4.20%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Neuropsychology publishes original, empirical research; systematic reviews and meta-analyses; and theoretical articles on the relation between brain and human cognitive, emotional, and behavioral function.